Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Biotechnology

Healthcare
$42.53 -1.86%

-$0.62 today

Market cap
$800.84M
Beta
1.18
P/E (TTM)
1.7
EPS (TTM)
$19.78
52W Low $18.14High $52.24

Volume 0.24M

Average 0.36M

RIGL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Rigel Pharmaceuticals, Inc.NASDAQ: RIGL

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $11.68M rose 38.4% year over year, behind the +41.7% change in trailing-twelve-month research & development. Sequentially, it rose 9.3% from the prior quarter. Over 3 fiscal years it compounded at -17.9% a year.

Context

  • Research & development amounted to 11.3% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +38.4% toward the trailing-twelve-month pace of +41.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$11.68M+9.3% QoQ
Last fiscal yearDec 2025
$33.3M+42.4% YoY
LTMMar 2026
$36.54M+41.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+38.4%——
1 year+42.4%——
3-year CAGR-17.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
33.3M USD
Year-over-year change
+42.4%
4-year CAGR
-15.5%

Research & Development vs competitors

How RIGL compares with its peers on the latest reported figures

  • RIGL's LTM Mar 2026 research & development of $36.54M is the 8th highest of the 10 companies compared; the peer median is $101.77M.
  • Its year-over-year change of +41.7% is the highest of 9, against a peer median of -9.2%.
  • Research & development amounts to 12.2% of revenue for RIGL, versus a peer median of 291.9%.
RIGL Competitors Peer median
Research & Development for RIGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EXELExelixis, Inc.LTM Jul 2026$824.32M -6.8%-2.6%33.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$331.95M +10.2%+18.6%47.3%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$188.07M +22.3%+26.8%—
VSTMVerastem, Inc.LTM Mar 2026$123.67M +33.3%+31.4%249.4%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$101.77M -11.6%-4.0%291.9%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$66.71M -38.5%-7.9%—
ANLAdlai Nortye Ltd.LTM Jun 2024$56.93M —-15.5%877.1%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$36.54M +41.7%-17.9%12.2%
CRDFCardiff Oncology, Inc.LTM Mar 2026$31.62M -19.6%+9.2%6022.3%
MREOMereo BioPharma Group plcLTM Mar 2026$18.13M -12.8%-16.7%3625.8%
Peer median (excluding RIGL) $101.77M-9.2%-2.6%291.9%

Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue149.24M120.24M116.88M179.28M294.28M
Cost of Revenue1.08M1.75M7.11M18.65M19.62M
Gross Profit148.15M118.49M109.77M160.63M274.66M
Gross Margin99.3%98.5%93.9%89.6%93.3%
Research & Development65.24M60.27M24.52M23.38M33.3M
Selling, General & Admin91.89M112.45M105.74M113.06M115.9M
Operating Expenses160.65M174.04M130.26M136.44M149.2M
Depreciation & Amortization1.16M998K1.24M2.23M2.42M
EBITDA(11.29M)(53.87M)(16.98M)28.51M131.56M
EBITDA Margin-7.6%-44.8%-14.5%15.9%44.7%
Operating Income(12.5M)(55.55M)(20.49M)24.19M125.47M
Operating Margin-8.4%-46.2%-17.5%13.5%42.6%
Interest Income47K684K2.27M2.09M3.68M
Interest Expense4.86M3.71M6.87M7.92M7.32M
Other Income / Expenses(4.81M)(3.02M)(4.6M)(5.83M)(3.64M)
Income Before Tax(17.31M)(58.57M)(25.09M)18.37M121.83M
Pre-Tax Margin-11.6%-48.7%-21.5%10.2%41.4%
Income Tax Expense605K00881K(245.2M)
Net Income(17.91M)(58.57M)(25.09M)17.49M367.02M
Net Margin-12.0%-48.7%-21.5%9.8%124.7%
EPS (Basic)(1.10)(3.40)(1.44)0.9920.40
EPS (Diluted)(1.10)(3.40)(1.44)0.9919.48
Weighted Avg Shares17.05M17.24M17.4M17.58M17.99M
Weighted Avg Shares (Diluted)17.05M17.24M17.4M17.69M18.84M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Intrinsic Alpha fair value

Locked

Current Price

$42.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.